What Wellington Partners does

Wellington Partners is a privately held European venture capital firm founded in 1998, headquartered in Munich (Türkenstraße 5, 80333 Munich) with an advisory entity in Zurich (Wellington Partners Advisory AG, Seidengasse 16, 8001 Zurich). The firm invests in early- and growth-stage life science companies across therapeutics, medical devices, diagnostics, digital health and industrial biotechnology, deploying equity tickets of EUR 2-20 million and co-leading or syndicating rounds across Europe. Capital is raised through closed-end fund vintages — WP I (1998, EUR 10m), WP II (2000, EUR 35m life science allocation), WPLS III (2007, EUR 78m), WPLS IV (2012, EUR 85m) and the current flagship WPLS V (2017, EUR 210m) — with limited partners including the European Investment Fund, the European Investment Bank, family offices, trusts and insurance companies.

The firm reports 58 life science investments, EUR 590 million cumulatively raised for life science funds, and 27 exits, IPOs and trade sales. Wellington's investment team combines Managing Partners Dr. Rainer Strohmenger, Harald Keller, Ernst Mannheimer and Karl Naegler (joined 2020) with Partners Dr. Varun Gupta and Dr. Johannes Fischer (both promoted November 2023), supported by Venture Partners and Venture Advisors with MD/PhD backgrounds. The firm sources 600+ investment proposals annually through its proprietary scientific and commercial network and supports portfolio companies on board-level strategy, regulatory navigation, and market entry into Europe, the U.S. and Asia. The firm is a signatory to the UN Principles for Responsible Investment and publishes an annual Impact & ESG Report.

Revenue mechanics are standard venture capital economics: management fees on committed/invested capital across fund vintages and carried interest on successful exits. Wellington has backed high-profile exits including Actelion (acquired by J&J), Definiens (AstraZeneca/MedImmune), Themis Bioscience (MSD), Symetis (Boston Scientific, USD 435m), Oxford Immunotec (PerkinElmer), Rigontec (MSD), and ImCheck Therapeutics (Ipsen, up to EUR 1bn total consideration). Current portfolio holdings include AMBOSS, NUCLIDIUM, Seamless Therapeutics, ONWARD Medical, Immatics, Quanta Dialysis Technologies, UroMems, MinervaX, Carisma Therapeutics, Beren Therapeutics and many others across multiple financing stages.

Name

Wellington Partners

Legal name

Wellington Partners Advisory AG

Website

http://www.wellington-partners.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Wellington Partners is a Munich-based European venture capital firm founded in 1998 that invests in early- and growth-stage life science companies, managing EUR 590m across five fund vintages with 58 portfolio investments and 27 realized exits.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

akta.pro secondary industry

Late-Stage Venture Capital (Series C+) (FSANAAAC)

Keywords

• Venture capital investing
• Life sciences investment
• Early-stage funding
• Growth-stage equity
• European venture capital

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

1. Venture capital fund management fees and carried interest: Wellington Partners raises dedicated life-science funds (WPLS I through WPLS V) and invests from them. Revenue is generated through typical VC economics: management fees on committed/invested capital and carried interest on successful exits (e.g., 21 exits to date from 53 deals). Investors include the European Investment Fund, the European Investment Bank, family offices, trusts, insurance companies and other financial institutions.
2. Capital gains from successful portfolio exits and IPOs: Realized returns from successful exits and IPOs, including Actelion (J&J), Definiens (AstraZeneca/MedImmune), Themis Bioscience (acquired by MSD), invendo medical (acquired by Ambu), Atopix Therapeutics (acquired by Chiesi Group), Symetis (acquired by Boston Scientific for USD 435m), Oxford Immunotec (acquired by PerkinElmer), Rigontec (acquired by MSD), ImCheck Therapeutics (acquired by Ipsen), and others.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Wellington Partners is a European venture capital firm that raises closed-end life science funds and invests the capital as direct equity in early- and growth-stage life science companies across Therapeutics, Medical Devices, Diagnostics, Digital Health and Industrial Biotechnology. The firm provides capital (typically EUR 2-20 million per round), board-level strategic support and access to a global scientific and commercial network to help portfolio companies advance through clinical development, regulatory approval and market entry. Revenue is generated through management fees on committed/invested capital and carried interest on successful exits.

Product overview

Wellington Partners is a European venture capital firm offering a portfolio of life sciences-focused fund vehicles, organized as a sequence of successive fund generations (WP I, WP II, WPLS III, WPLS IV, and the current flagship WPLS V), plus a legacy Tech Investments vertical. The offering is structured as a family of fund products rather than a single unified software product, with each successive fund vehicle building on the prior generation's investment thesis in early- and growth-stage life science companies; WPLS V is the active core product with EUR 210 million deployed across 15 investments, while the earlier WP I, WP II, WPLS III, and WPLS IV vehicles represent prior-generation fund products.

Differentiator

Problem solved

Functional benefit

Products and services

• Wellington Life Science V (WPLS V) Fund Current main life sciences venture capital fund; EUR 210 million fund size with 15 portfolio investments to date, focusing on early- and growth-stage life science companies across Therapeutics, Medical Devices, Diagnostics, Digital Health and Industrial Biotechnology. Available to qualified institutional limited partners (LPs).
• Wellington Life Science IV (WPLS IV) Fund Prior-generation life sciences fund; EUR 85 million fund size with 14 portfolio investments, used as the predecessor vehicle to WPLS V.
• Wellington Life Science III (WPLS III) Fund Earlier-generation life sciences fund; EUR 78 million fund size with 13 portfolio investments.
• Wellington Partners II (WP II) Fund Second-generation fund combining life sciences and technology investments; EUR 35 million allocated to life sciences across 4 life science investments.
• Wellington Partners I (WP I) Fund Firm's inaugural fund; EUR 10 million allocated to life sciences across 9 life science investments, launched concurrently with the firm's founding.
• Direct Equity Investments in Life Science Portfolio Companies Direct minority and lead/co-lead equity investments of EUR 2-20 million per round into early- and growth-stage life science companies, paired with board-level strategic support, clinical and regulatory guidance, and global market entry support into Europe, the U.S. and Asia. Targeted at founders and management teams of portfolio companies.
• Tech Investments (Legacy Vertical) Legacy technology investment vertical that Wellington Partners continues to support for its existing technology portfolio; the firm has ceased making new technology investments.

Quantifiable outcome

• EUR 590m raised for life science funds
• +5 more outcomes

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

62 partnerships are on record, tiered core portfolio company investment target, co-lead investor; flagship radiotheranostics holding, existing investor participating in series a, major pharma co-development/licensing partner via portfolio company, long-standing portfolio company; public company (nasdaq: imtx), successful exit via acquisition by ipsen, long-standing portfolio company; flagship neurotech holding, regulatory partner via portfolio company, portfolio company in digital health, portfolio company investment target, new investor; clinical-stage liver regeneration asset, long-standing portfolio company; growth-stage investment target, public payer partner via portfolio company, diagnostics commercial partner via portfolio company, public funding partner via portfolio company, new portfolio investment, long-standing portfolio company; multiple rounds, pharma co-development partner via portfolio company, long-standing portfolio company investment target, major pharma co-development partner via portfolio company, early-stage portfolio company, pharma discovery collaboration via portfolio company, flagship seed-stage portfolio company, major pharma licensing partner via portfolio company, diagnostics licensing partner via portfolio company, industry r&d partner via portfolio company, distribution partner via portfolio company, major pharma discovery partner via portfolio company, long-standing portfolio company; multi-round investor, successful exit (acquisition), successful exit; portfolio company acquired by msd, portfolio company; exited via ipsen acquisition (oct 2025), academic licensing partner via portfolio company, academic / clinical partner via portfolio company and successful exit (acquisition chain).

• Beren Therapeutics P.B.C.core portfolio company investment targetStrategic or Co-development Partner · 10 June 2026Wellington Partners participated in Beren Therapeutics' $135 million equity financing (part of a $300m combined package). Beren is a clinical-stage biotech developing adrabetadex, an investigational cyclodextrin therapy for infantile-onset Niemann-Pick disease type C with a PDUFA target action date of November 17, 2026. Wellington is a current investor.
• NUCLIDIUM AGco-lead investor; flagship radiotheranostics holdingStrategic or Co-development Partner · 27 May 2026Wellington Partners co-led the oversubscribed CHF 26.4m (EUR 28.4m) Series B extension, bringing the total Series B to CHF 105m (~EUR 115m), and previously co-led the EUR 84m initial Series B. The financing accelerates clinical development of NU101 (mCRPC) and NU201 (mBC) copper-based radiotheranostics and the buildout of a global production network. Other co-leads include Kurma Growth Opportunities Fund, Angelini Ventures and Neva SGR.
• nyra health (Vienna)existing investor participating in series aStrategic or Co-development Partner · 24 February 2026Wellington Partners participated as an existing investor in nyra health's €20 million Series A round led by Armira Growth, with co-investors Crane Venture Partners and EVER Pharma. nyra health operates the AI-driven myReha platform in 100+ rehabilitation clinics across the DACH region.
• Eli Lilly and Company (Lilly) — Seamless Therapeutics collaborationmajor pharma co-development/licensing partner via portfolio companyStrategic or Co-development Partner · 28 January 2026Seamless Therapeutics (Wellington Partners portfolio company) entered a global research collaboration and licensing agreement with Eli Lilly to develop programmable recombinase-based therapeutics for hearing loss. Seamless is eligible for over $1.12 billion in development and commercial milestones plus tiered royalties.
• Immatics (TCR Bispecifics pipeline)long-standing portfolio company; public company (nasdaq: imtx)Strategic or Co-development Partner · 12 November 2025Wellington Partners has been a long-standing Immatics investor. In November 2025, Immatics achieved clinical proof-of-concept for IMA402 (PRAME) and IMA401 (MAGEA4/8) TCR Bispecifics with favorable tolerability and durable responses.
• ImCheck Therapeuticssuccessful exit via acquisition by ipsenStrategic or Co-development Partner · 22 October 2025Wellington Partners was an existing investor in ImCheck Therapeutics, whose acquisition by Ipsen was announced for a closing purchase price of EUR 350m plus up to EUR 1bn in contingent milestone payments. ImCheck pioneers next-generation immuno-oncology via its ICT01 anti-BTN3A monoclonal antibody for AML.
• ONWARD Medicallong-standing portfolio company; flagship neurotech holdingStrategic or Co-development Partner · 8 September 2025Wellington Partners is a long-standing investor in ONWARD Medical, supporting the company through CE Mark for ARC-EX (September 2025), FDA clearance, and largest early-stage medtech IPO in European history. Dr. Regina Hodits is referenced for completing the IPO.
• U.S. FDA and French ANSM (regulators) — UroMems clearanceregulatory partner via portfolio companyOthers · 17 July 2025UroMems (Wellington Partners portfolio company) received FDA IDE approval and French ANSM clearance to initiate the landmark SOPHIA2 pivotal clinical study of the UroActive smart implant.
• Aktiia / Hiloportfolio company in digital healthStrategic or Co-development Partner · 2 May 2025Swiss HealthTech startup Aktiia (Wellington Partners portfolio company) raised €37 million in Series B funding and rebranded to Hilo, supporting product innovation, market expansion, and enterprise platform development for blood pressure monitoring technology. Wellington is referenced as a portfolio company investor.
• Aktiia (now Hilo) — Series Bportfolio company investment targetStrategic or Co-development Partner · 1 May 2025Aktiia (Wellington Partners portfolio company) secured $42 million in Series B funding in May 2025 and rebranded to Hilo. Subsequent $100m+ funding and FDA clearance for G0 band were secured in 2025.
• HepaRegeniX GmbHnew investor; clinical-stage liver regeneration assetStrategic or Co-development Partner · 15 April 2025Wellington Partners joined as a new investor in HepaRegeniX's €21.5 million financing round to support clinical advancement of HRX-215, a liver regeneration candidate that inhibits MKK4, with plans to advance Phase Ib and Phase IIa trials.
• AMBOSSlong-standing portfolio company; growth-stage investment targetStrategic or Co-development Partner · 25 March 2025Wellington Partners backed AMBOSS's €240 million financing round to expand AMBOSS' position as a leading co-pilot for physicians worldwide, alongside other funding rounds over many years (€30m Series B in 2019).
• Deutsche Rentenversicherung (German Pension Insurance)public payer partner via portfolio companyOthers · 30 January 2025nyra.health (Wellington Partners portfolio company) became a recognized provider of digital rehabilitation aftercare for Deutsche Rentenversicherung, Germany's statutory pension insurance.
• U.S. FDA (regulator) — Quanta Dialysis clearanceregulatory partner via portfolio companyOthers · 4 November 2024The U.S. FDA granted Quanta Dialysis Technologies (Wellington Partners portfolio company) clearance for the Quanta™ Dialysis System for home hemodialysis in November 2024.
• Aignosticsportfolio company investment targetStrategic or Co-development Partner · 29 October 2024Wellington Partners participated in Aignostics' $34 million Series B to enhance precision medicine with AI. Aignostics also announced results for a pathology foundation model developed in collaboration with Mayo Clinic in January 2025.
• Beckman Coulter — SphingoTec kidney biomarker partnershipdiagnostics commercial partner via portfolio companyStrategic or Co-development Partner · 9 October 2024SphingoTec (Wellington Partners portfolio company) partnered with Beckman Coulter to improve kidney health assessment in critical care, leveraging SphingoTec's penKid biomarker.
• European Innovation Council and France 2030public funding partner via portfolio companyStrategic or Co-development Partner · 19 September 2024UroMems' UroActive pivotal project is financially supported by the European Innovation Council and France 2030.
• CorFlow Therapeutics AGportfolio company investment targetStrategic or Co-development Partner · 10 September 2024Wellington Partners participated in CorFlow Therapeutics AG's €44 million Series B financing to support the advancement of a novel diagnostic and drug delivery platform for microvascular obstruction (MVO) in heart attack patients. CorFlow also received FDA approval of the MOCA-II IDE Pivotal Trial in 2025.
• SciRhomnew portfolio investmentStrategic or Co-development Partner · 9 July 2024Wellington Partners announced a new investment in SciRhom in July 2024, expanding its life science portfolio.
• UroMems (Series C)long-standing portfolio company; multiple roundsStrategic or Co-development Partner · 25 June 2024Wellington Partners backed UroMems' $47m (€44m) Series C in June 2024 to fund pivotal clinical trials of the UroActive System, the first smart automated implant for stress urinary incontinence. Wellington first invested in UroMems in November 2016 and led the €23m Series B in April 2021.
• Bayer — Aignostics precision oncology collaborationpharma co-development partner via portfolio companyStrategic or Co-development Partner · 14 March 2024Aignostics (Wellington Partners portfolio company) announced a collaboration with Bayer to develop next-generation precision oncology solutions using Aignostics' AI-powered pathology platform.
• MMI (Medical Microinstruments)portfolio company investment targetStrategic or Co-development Partner · 21 February 2024Wellington Partners participated in MMI's $110 million Series C Financing. MMI received FDA authorization to commercialize the Symani® Surgical System in the U.S. in April 2024.
• MinervaXlong-standing portfolio company investment targetStrategic or Co-development Partner · 11 October 2023Wellington Partners backed MinervaX's upsized EUR 54M financing in October 2023 (with prior €72m financing in 2022 and €47.4m in 2020) to advance the development of its maternal vaccine against Group B Streptococcus.
• Moderna — Immatics multi-platform oncology collaborationmajor pharma co-development partner via portfolio companyStrategic or Co-development Partner · 11 September 2023Immatics (Wellington Partners portfolio company) and Moderna announced a strategic multi-platform collaboration to develop innovative oncology therapeutics.
• Moderna — Carisma Therapeutics in vivo CAR-M collaborationpharma co-development partner via portfolio companyStrategic or Co-development Partner · 10 September 2023Carisma Therapeutics (Wellington Partners portfolio company) has an ongoing collaboration with Moderna to develop in vivo CAR-M therapies for oncology and autoimmune diseases. The partnership was expanded in September 2024 to develop two in vivo CAR-M therapies for autoimmune diseases.
• nyra health (seed round)early-stage portfolio companyStrategic or Co-development Partner · 22 June 2023Wellington Partners participated in nyra health's €4.5m Seed Round to advance its digital neuro-therapy platform, prior to participating in the €20m Series A in February 2026.
• Daiichi Sankyo — Confo Therapeutics CNS collaborationpharma discovery collaboration via portfolio companyStrategic or Co-development Partner · 30 March 2023Confo Therapeutics (Wellington Partners portfolio company) entered a collaboration agreement with Daiichi Sankyo to discover novel medicines for CNS diseases using Confo's proprietary ConfoBody platform.
• Seamless Therapeuticsflagship seed-stage portfolio companyStrategic or Co-development Partner · 16 March 2023Wellington Partners backed Seamless Therapeutics' $12.5M Seed Financing at launch in March 2023 to advance its programmable recombinase-based gene editing platform. Seamless subsequently entered a global research collaboration with Lilly for hearing loss therapeutics (January 2026, $1.12bn+ biobucks).
• Eli Lilly and Company (Lilly) — Confo Therapeutics licensingmajor pharma licensing partner via portfolio companyStrategic or Co-development Partner · 2 March 2023Confo Therapeutics (Wellington Partners portfolio company) entered a worldwide licensing agreement with Eli Lilly for CFTX-1554 and back-up compounds (peripheral pain candidate targeting AT2R), with $40m upfront and up to $590m in potential milestones per program plus tiered royalties. In April 2026, the first Phase 2a patients were dosed.
• TRiCares (TRiCares)portfolio company investment targetStrategic or Co-development Partner · 13 December 2022Wellington Partners backed TRiCares' Series C financing (€51m raised December 2022) for the minimally invasive Topaz tricuspid heart valve replacement system. Wellington has been an investor in TRiCares since at least 2018 (€22m Series B).
• Boditech Med — SphingoTec global licensingdiagnostics licensing partner via portfolio companyStrategic or Co-development Partner · 17 November 2022SphingoTec (Wellington Partners portfolio company) closed a global licensing agreement with Boditech Med for kidney function biomarker Proenkephalin A 119-159 (penKid).
• WACKER — NEUWAY Pharma CNS research projectindustry r&d partner via portfolio companyStrategic or Co-development Partner · 13 October 2022NEUWAY Pharma (Wellington Partners portfolio company) and WACKER launched a research project to develop RNA-based actives for the treatment of central nervous system diseases.
• Virgin Pulse — Koa Health partnershipdistribution partner via portfolio companyGTM or Marketing Partner · 12 May 2022Koa Health (Wellington Partners portfolio company) partnered with Virgin Pulse to extend mental health programs via the VP+ Program.
• Sidekick Healthportfolio company investment targetStrategic or Co-development Partner · 9 May 2022
• Bristol Myers Squibb — Immatics IMA401 global exclusive licensemajor pharma licensing partner via portfolio companyStrategic or Co-development Partner · 14 December 2021Immatics (Wellington Partners portfolio company) entered a global exclusive license with Bristol Myers Squibb for its TCR Bispecific program IMA401, with $58m financing in 2017 to support the program.
• Regeneron — Confo Therapeutics collaborative agreementmajor pharma discovery partner via portfolio companyStrategic or Co-development Partner · 7 December 2021Confo Therapeutics (Wellington Partners portfolio company) entered a collaborative agreement with Regeneron to discover novel GPCR-targeting medicines using Confo's ConfoBody platform.
• iOmx Therapeuticsportfolio company investment targetStrategic or Co-development Partner · 6 October 2021Wellington Partners invested in iOmx Therapeutics' EUR 65 million Series B round. Wellington first invested via a €40m Series A in 2016.
• Quanta Dialysis Technologieslong-standing portfolio company; multi-round investorStrategic or Co-development Partner · 23 June 2021Wellington Partners has backed Quanta since its Series A and participated in subsequent rounds including the $245m Series D-equivalent (2021), $48m Series C (2019), and growth funding. Quanta received FDA 510(k) clearance for the SC+ Hemodialysis System in January 2021 and FDA clearance for home hemodialysis in November 2024.
• PerkinElmer / Oxford Immunotecsuccessful exit (acquisition)Strategic or Co-development Partner · 8 January 2021PerkinElmer acquired Oxford Immunotec Global PLC, a Wellington Partners portfolio company, in January 2021.
• Sidekick Health (Series A)portfolio company investment targetStrategic or Co-development Partner · 28 October 2020Wellington Partners led Sidekick Health's $20M Series A funding round (October 2020, with Asabys) for its digital therapeutics platform. Sidekick was subsequently chosen as a partner for the White House's CancerX project in April 2023.
• Themis Bioscience / MSD acquisitionsuccessful exit; portfolio company acquired by msdStrategic or Co-development Partner · 26 May 2020Themis Bioscience, a Wellington Partners portfolio company developing vaccines (including for Chikungunya), was acquired by MSD in May 2020. Previously raised EUR 40m Series D in 2019, EUR 10m Series C in 2018, and partnered with CEPI for Lassa/MERS and Chikungunya vaccines.
• SIRS Therapeutics / F4 Pharmaportfolio company investment targetStrategic or Co-development Partner · 15 April 2020Wellington invested in SIRS Therapeutics to develop FX06 for treatment of ARDS in COVID-19 patients in collaboration with F4 Pharma.
• ImCheck Therapeuticsportfolio company; exited via ipsen acquisition (oct 2025)Strategic or Co-development Partner · 4 December 2019Wellington Partners participated in ImCheck's $53m Series B in December 2019. ImCheck later raised an upsized EUR 96m (USD 103m) financing in June 2022. The company was acquired by Ipsen in October 2025 for up to EUR 1bn in total consideration.
• eGenesislong-standing portfolio company; multiple roundsStrategic or Co-development Partner · 7 November 2019Wellington Partners participated in eGenesis' $100m Series B in November 2019 and $125m Series C in March 2021. eGenesis is developing human-compatible organs and cells (genetically engineered porcine) for transplant patients.
• STipe Therapeuticsportfolio company investment targetStrategic or Co-development Partner · 30 September 2019Wellington Partners co-led the EUR 20 million Series A financing of STipe Therapeutics, which targets innate immunity for oncology. Dr. Claus Elsborg Olesen is CEO.
• Celgene (Bristol Myers Squibb) — Immatics strategic collaborationmajor pharma co-development partner via portfolio companyStrategic or Co-development Partner · 28 August 2019Immatics (Wellington Partners portfolio company) entered a strategic collaboration with Celgene to develop novel adoptive cell therapies. Immatics subsequently expanded its alliance with Bristol Myers Squibb in 2022 to develop allogeneic gamma delta cell therapy programs, and received $35m equity investment from BMS in 2023 plus a global exclusive license for IMA401 in 2021.
• MSD (Merck) — Themis license and research collaborationmajor pharma licensing partner via portfolio companyStrategic or Co-development Partner · 22 August 2019Themis (Wellington Partners portfolio company) announced an exclusive license and research collaboration agreement with MSD to develop vaccine candidates. Themis was subsequently acquired by MSD in May 2020.
• Confo Therapeuticsportfolio company investment targetStrategic or Co-development Partner · 7 May 2019Wellington Partners co-led the €30 million Series A financing in Confo Therapeutics, a GPCR drug discovery company. Dr. Cedric Ververken is CEO. Wellington is a long-standing investor.
• Adrenomedportfolio company investment targetStrategic or Co-development Partner · 26 November 2018Wellington Partners co-led Adrenomed's €24 million financing in November 2018 (with HBM). Wellington is referenced as a long-standing, dedicated leading VC. Adrenomed develops adrecizumab for endothelial barrier dysfunction.
• Max-Planck-Innovationacademic licensing partner via portfolio companyStrategic or Co-development Partner · 11 October 2018Themis (Wellington Partners portfolio company) announced an exclusive licensing agreement with Max-Planck-Innovation to develop and commercialize oncolytic virotherapies.
• SphingoTecportfolio company investment targetStrategic or Co-development Partner · 9 October 2018Wellington Partners co-led SphingoTec's €20 million financing in October 2018 (with HBM). SphingoTec develops kidney function biomarkers.
• Carisma Therapeuticslong-standing portfolio company; multiple roundsStrategic or Co-development Partner · 27 June 2018Wellington Partners co-led Carisma Therapeutics' $53m Series A in 2018, participated in the $47m Series B in 2021, and has supported the company through merger with Sesen Bio (March 2023) and FDA IND clearance. Carisma's lead programs target HER2-overexpressing solid tumors and liver fibrosis.
• Mayo Clinic — Aignostics collaborationacademic / clinical partner via portfolio companyStrategic or Co-development Partner · 9 January 2018Aignostics (Wellington Partners portfolio company) announced results in January 2025 for a pathology foundation model developed in collaboration with Mayo Clinic.
• Ambu / invendo medicalsuccessful exit (acquisition)Strategic or Co-development Partner · 25 October 2017Ambu acquired Wellington Partners portfolio company invendo medical in October 2017. invendo medical had received CE mark and FDA clearance for the Invendoscopy E200 System.
• MSD / Rigontecsuccessful exit (acquisition)Strategic or Co-development Partner · 6 September 2017MSD acquired Rigontec, a Wellington Partners portfolio company developing RIG-I agonists (RGT100), in September 2017.
• Immaticslong-standing portfolio company; multiple roundsStrategic or Co-development Partner · 10 April 2017Wellington Partners has been a long-standing investor in Immatics, participating in a $58m financing in October 2017, $35m equity from BMS in July 2023, and $110m underwritten offering in October 2022. Immatics went public on NASDAQ via business combination in July 2020.
• Chiesi Group / Atopix Therapeuticssuccessful exit (acquisition)Strategic or Co-development Partner · 17 November 2016Chiesi Group acquired Atopix Therapeutics, a Wellington Partners portfolio company developing treatments for inflammatory and respiratory diseases, in November 2016.
• UroMems (Series A)portfolio company investment targetStrategic or Co-development Partner · 15 November 2016Wellington Partners invested in UroMems in November 2016 as an early investor, with continued participation through multiple subsequent rounds.
• iOmx Therapeutics (Series A)portfolio company investment targetStrategic or Co-development Partner · 22 September 2016Wellington Partners invested in iOmx's €40m Series A in September 2016, with continued participation in subsequent Series B in October 2021.
• Boston Scientific / Symetis / Middle Peak Medicalsuccessful exit (acquisition chain)Strategic or Co-development Partner · 12 May 2016Symetis (a Wellington Partners portfolio company) acquired Middle Peak Medical in May 2016; Boston Scientific subsequently acquired Symetis for USD 435m in cash.
• AstraZeneca / MedImmune / Definienssuccessful exit (acquisition)Strategic or Co-development Partner · 1 June 2014AstraZeneca and its R&D division MedImmune acquired Definiens, a Wellington Partners portfolio company developing Tissue Phenomics technology, in June 2014.
• Johnson & Johnson / Actelionsuccessful exit (acquisition)Strategic or Co-development Partner · 1 March 2001Johnson & Johnson acquired Actelion, a Wellington Partners portfolio company developing products for pulmonary arterial hypertension. Actelion went public on the Swiss Stock Exchange in 2000.

Scale indicators10 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Sofinnova Partners: Paris-headquartered European venture capital firm focused exclusively on life sciences across therapeutics, medtech, and digital health. Closely comparable as a European life-science-only specialist with multi-decade track record and similar fund sizes.
• Forbion: Dutch life-sciences-focused venture capital firm investing in early- and growth-stage therapeutic and medical-device companies. Highly comparable in geographic focus, sector specialization, and fund strategy.
• LSP (Life Sciences Partners): Amsterdam-based European venture capital firm dedicated to life sciences, investing from early to growth stage across therapeutics and medical devices. Direct competitor for European life-science deals of similar size and stage.
• Abingworth: UK-based venture capital firm with a life-sciences franchise investing across Europe and the U.S. Comparable as a transatlantic life-science VC with crossover and later-stage capabilities.
• Versant Ventures: Healthcare-focused venture capital firm with offices in North America and Europe investing across therapeutics, medical devices, and diagnostics. Direct peer in the European life-science investment strategy.

Broad incumbents

• Index Ventures: Large European-headquartered venture capital firm with both technology and life-sciences franchises. Comparable as a European VC competing for life-science deals but operating across multiple sectors at much larger AUM scale.
• Novo Holdings (Novo Ventures): Denmark-based investment arm of the Novo Nordisk Foundation with a substantial life-sciences venture franchise. Comparable as a large, well-capitalized European life-science investor, though backed by a foundation.

Regional players

• Earlybird Venture Capital: Berlin-based European venture capital firm with both technology and health-tech/biotech funds. Comparable as a Munich/Berlin-anchored European VC with life-science exposure, though more tech-weighted.

Emerging players

• SR One (GSK): Venture capital arm of GSK investing in early-stage life-science companies. Comparable as a life-science VC, though corporate-strategic in nature with different return expectations.
• M Ventures (Merck KGaA): Corporate venture arm of Merck KGaA investing across life sciences and other sectors. Partially comparable as a strategic life-science investor in Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/wellingtonvc
• Facebookfacebook.com/wellingtonpartners
• LinkedInlinkedin.com/company/wellington-partners

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments256 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellington Partners